Details of the Drug Combinations

General Information of This Drug (ID: DMDEXQ0)

• Drug Name: Febuxostat (DMDEXQ0)
• Synonyms: Adenuric; TEI; Uloric; Febuxostat [USAN]; S1547; TMX 67; Tei 6720; TMX-67; Tei-6720; Uloric (TN); Febuxostat (JAN/USAN/INN); TMX-67, Adenuric, Uloric, Febuxostat; 111GE013; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid

Indication

Hyperuricaemia; ICD 11: 5C55.Y; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Febuxostat + Lesinurad	DCAX8DV	Lesinurad	Tophaceous Gout	[2]
Febuxostat + Colchicine	DCIG6OC	Colchicine	Gout	[3]
Methotrexate + Febuxostat	DC6MNXU	Methotrexate	Drug Interaction	[4]
Febuxostat + Lansoprazole	DC5LB46	Lansoprazole	Gout	[5]
Febuxostat + M102	DC0WGVW	M102	Gout	[6]
Febuxostat + M102	DCGZRKA	M102	Hyperuricemia	[7]
RDEA3170 + Febuxostat	DCWDX6A	RDEA3170	Asymptomatic Hyperuricemia	[8]
RDEA3170 + Febuxostat	DCGPRCC	RDEA3170	Asymptomatic Hyperuricemia	[8]
Febuxostat + Lansoprazole	DCZ2S89	Lansoprazole	Gout	[9]
Febuxostat + Colchicine	DC6R8CU	Colchicine	Primary Gout	[10]
Febuxostat + Allopurinol	DCNHQKA	Allopurinol	Adenine Phosphoribosyltransferase Deficiency	[11]
Omeprazole + Febuxostat	DCEGNCJ	Omeprazole	Gout	[12]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6817).
• [2] ClinicalTrials.gov (NCT01510769) Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
• [3] ClinicalTrials.gov (NCT01112982) An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
• [4] ClinicalTrials.gov (NCT05575297) A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin and Febuxostat on the Pharmacokinetics of Methotrexate in Healthy Subjects
• [5] ClinicalTrials.gov (NCT02128490) Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
• [6] ClinicalTrials.gov (NCT02252835) Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
• [7] ClinicalTrials.gov (NCT01416402) Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
• [8] ClinicalTrials.gov (NCT03316131) A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
• [9] ClinicalTrials.gov (NCT02139046) Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
• [10] ClinicalTrials.gov (NCT02060552) Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels
• [11] ClinicalTrials.gov (NCT02752633) Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion
• [12] ClinicalTrials.gov (NCT02500641) Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout